Immunol Lett 2001 Oct 1;78(3):183-7
Boylan MT, Crockard AD, McDonnell GV, McMillan SA, Hawkins SA.
Department of Microbiology and Immunobiology, Queen's University of Belfast, Royal Group of Hospitals Trust, Grosvenor Road, BT12 6BA, Northern Ireland, Belfast, UK
Elevated sFas levels have been described in multiple sclerosis (MS) patients with active disease.
The aim of this study was to assess the diagnostic potential of serum and cerebrospinal fluid (CSF) sFas measurements in differentiating clinically defined MS patient subgroups.
Levels of sFas and sFas indices were determined in patients with stable relapsing-remitting MS (RRMS), active RRMS, primary progressive MS (PPMS), secondary progressive MS (SPMS) and patients with inflammatory (IND) and noninflammatory neurological diseases (NIND).
Serum sFas modulation over 32 weeks IFN-beta1a therapy was also investigated. Serum and CSF sFas levels and sFas indices were elevated in MS compared to NIND and IND patients.
Within the MS group, serum and CSF sFas levels were highest in PPMS, with active RRMS patients demonstrating the highest sFas indices.
This may reflect an ongoing disease process which is occurring acutely (active disease) or incessantly (progressive disease).
IFN-beta1a induced a transient increase in circulating sFas following initiation of therapy. Whilst evidence was provided for variable sFas expression in clinical subgroups of MS, there was insufficient definition between the respective groups to advocate sFas measurements as a diagnostic marker of clinical subgroups of MS.
PMID: 11578693 [PubMed - in process]